Abstract 238P
Background
The EV-301 trial showed the efficacy of Enfortumab-Vedotin (EV) in the 3rd-line therapy for metastatic Urothelial Carcinoma (mUC) previously treated with platinum-combined chemotherapy and immune-checkpoint inhibitor. Here we showed an initial report of EV in our institution.
Methods
25 patients (Pts) with mUC received EV from January 2021 to July 2023 at our institution. EV was administered 10mg/kg weekly until disease progression. Whole-body CT scan was performed every two months(Ms). We retrospectively evaluated progression free survival based on RECIST version 1.1 as efficacy and adverse events (AEs) rate based on the National Cancer Institute CTCAE, version 4.03 as safety.
Results
Of 25 patients (Pts), with median age of 73 (54-85), 16 (64%) Pts had bladder tumor, 9(36%) Pts had upper urinary tract, 1 Pt had both upper and lower urinary tract as primary. 18(72%) Pts had lymph node metastasis (Mets), 14(56%) Pts had lung Mets, 5 (20%) Pts had liver Mets 4 (16%) Pts had bone Mets. 5(20%) Pts had 4 regimens, 7(28%) Pts had 3 regimens and 13(52%) Pts had 2 regimens of pre-treated systemic therapy for mUC. During the median follow-up period of 7.0 (2.1-16.2) Months, 9 (36%) Pt had died. The best response during follow-up period was CR in2(8%), PR in 11(44%), SD in 11(44%) and PD in1(4%) Pts. Median PFS was 10.5 Ms and OS was 13.0. 8 Severe AEs (more than Grade3) was occurred in 8 (32%) Pts, derimatosis was the highest occurrence AE and 65% patients had ermatosis. OS of patiets with prior taxane therapy was significantly worse than that of patients without prior taxane therapy (11.4M vs 14.1M, p=0.027).
Conclusions
Initial report of Enfortumab-Vedotin resulted in a median PFS of 10.5 Ms and 20% severe AE, which was as safe and effective as the report from clinical trial. OS of patients pre-treated with taxane therapy was significantly worse than that of patients without prior taxane therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract